Modified bacterial microcompartment shell protein
The present invention provides for a fusion protein comprising (1) a bacterial microcompartment (BMC) shell protein comprising one or more subunit, and (2) a first component of a specific-binding pair, operably linked to the BMC shell protein such that the first component faces (i) a lumen (inside) side, or (ii) outside of a BMC shell formed incorporating the fusion protein and the fusion protein does not disrupt or prevent the folding of the BMC shell protein or the ability of the BMC shell protein to integrate with other BMC shell proteins into a BMC shell; wherein the first component is capable of forming a stable or irreversible interaction with a second component of the specific-binding pair.
1. A method for titrating a range of BMC shells with variable permeability, the method comprising:
(a) determining a desired permeability for a BMC shell,
(b) forming a series of BMC shells with a variable amount of a fusion protein, comprising a BMC-P and a first component, relative to the amounts of the BMC-H and BMC-T shell proteins, and
(c) determining the permeability of each BMC shell formed with a specific amount of the fusion protein relative the amounts of the BMC-H and BMC-T shell proteins.
2. The method of claim 1 , wherein the step (b) forming comprises using an in vivo capped or ex vivo capped method.
3. The method of claim 1 , the method further comprising:
purifying or isolating each BMC shell formed with a specific amount of the fusion protein relative the amounts of the BMC-H and BMC-T shell proteins using a second component bound to a solid support; wherein the purifying or isolating step occurs after the (b) forming step and prior to the (c) determining step.
4. The method of claim 1 , the method further comprising:
(d) identifying the BMC shell of step (b) that has a permeability closest to the desired permeability determined in the determining a desired permeability for a BMC shell step.
5. The method of claim 1 , wherein the fusion protein comprises: (1) a bacterial microcompartment (BMC) shell protein comprising one or more subunit, and (2) a first component of a specific-binding pair, operably linked to the BMC shell protein such that the first component faces (i) a lumen side, or (ii) outside of a BMC shell formed incorporating the fusion protein and the fusion protein does not disrupt or prevent the folding of the BMC shell protein or the ability of the BMC shell protein to integrate with other BMC shell proteins into a BMC shell; wherein the first component is capable of forming a stable or irreversible interaction with a second component of the specific-binding pair.
6. The method of claim 5 , wherein the fusion protein comprises: (1) a bacterial microcompartment (BMC) shell protein comprising one or more subunit, and (2) a first component of a specific-binding pair, operably linked to the BMC shell protein such that the first component faces a lumen (inside) side, of a BMC shell formed incorporating the fusion protein and the fusion protein does not disrupt or prevent the folding of the BMC shell protein or the ability of the BMC shell protein to integrate with other BMC shell proteins into a BMC shell; wherein the first component is capable of forming a stable or irreversible interaction with a second component of the specific-binding pair.
7. The method of claim 5 , wherein the fusion protein comprises: (1) a bacterial microcompartment (BMC) shell protein comprising one or more subunit, and (2) a first component of a specific-binding pair, operably linked to the BMC shell protein such that the first component faces outside of a BMC shell formed incorporating the fusion protein and the fusion protein does not disrupt or prevent the folding of the BMC shell protein or the ability of the BMC shell protein to integrate with other BMC shell proteins into a BMC shell; wherein the first component is capable of forming a stable or irreversible interaction with a second component of the specific-binding pair.
8. The method of claim 5 , wherein the stable or irreversible interaction is a spontaneous formation of a covalent bond.
9. The method of claim 8 , wherein the covalent bond is an isopeptide bond.
10. The method of claim 9 , wherein (a) said first component is a peptide tag comprising a peptide fragment of an isopeptide protein, said tag having a length of at least 5 amino acids but no more than 50 amino acids, and comprises a first reactive residue involved in formation of an intramolecular isopeptide bond in an isopeptide protein, wherein said peptide tag is either unconjugated or is conjugated to a heterologous protein or peptide or to another molecule and wherein said isopeptide protein is selected from the group consisting of (i) major pilin protein Spy0128 from Streptococcus pyogenes as set forth in SEQ ID NO: 1 or a protein with at least 95% identity thereto capable of spontaneously forming an isopeptide bond, or (ii) FbaB from S. pyogenes as set forth in SEQ ID NO:2, or a protein with at least 80% identity thereto capable of spontaneously forming an isopeptide bond; (b) said binding partner (i) comprises a different fragment of an isopeptide protein as set forth in (a)(i) or (a)(ii) wherein said fragment is at least 20 amino acids in length and (ii) comprises a second reactive residue involved in the isopeptide bond in said isopeptide protein, wherein the binding partner does not include the first reactive residue of the peptide tag; and (c) said peptide tag and binding partner are capable of binding to each other and forming an isopeptide bond between the first and second reactive residues.
11. The method of claim 1 , wherein the BMC shell protein of the fusion protein is a BMC shell protein comprising a domain which forms the pentagonal vertice of the BMC shell.